AimFetal bowel dilatation (FBD) in the late trimester of pregnancy can be related with varies of prognosis. Our aims were to obtain antenatal factors that might have relevance for the distinct prognosis with FBD.MethodsSeven features of 68 pregnancies presented with FBD were assessed. The best cut‐off value to predict intestinal outcomes was selected using receiver‐operating characteristics curves, and the effective variables were included into a logistic regression model.ResultsThe best cut‐off valves to predict intestinal pathologies were 14.5 mm of fetus dilated loop and 37.7 weeks of gestational age at delivery, respectively. The congenital gastrointestinal tract anomalies included 24 cases (92.3%) of intestine atresia, 1 case (3.85%) of small intestine volvulus and 1 case (3.85%) of midgut malrotation.ConclusionFetal dilated loops and gestational age at delivery are both an independent risk factor for predicting intestinal pathologies of newborns, which should arouse high attention.
The present study provides a new transurethral seminal tract endoscopic technique with seminal vesicle scope through the normal anatomic tract to treat patients with chronic seminal vesiculitis. It proved to be easily conducted with minimized complications. Further investigations are needed to confirm our results.
The incidence of renal cell carcinoma (RCC) has been steadily rising each year. There are currently few recognized biomarkers for the diagnosis and prognosis of RCC. We investigated semenogelin I (Sg I) expression and its clinical significance in patients with RCC. The expression levels of Sg I and its protein were measured by qPCR and Western blotting, respectively. Immunohistochemistry was used to investigate the protein expression of Sg I in RCC and normal renal tissue from 53 patients. The Kaplan-Meier method and log-rank test were used to evaluate the data. By qRCR (p < 0.01) and Western blot, the level of Sg I expression in benign tissues was higher than that in RCC tissues. Expression of Sg I was observed in 30 (57 %) RCC cases, which was significantly lower than that observed in benign renal tissues from the same patients [Sg I positive in 53 (100 %) cases (p < 0.0001)] by immunohistochemistry. There was an inverse relation between Sg I expression and clinical stage (pT1-2 vs pT3-4, p < 0.0001). Patients with Sg I-negative tumor had a significantly higher risk of recurrence (Kaplan-Meier and log-rank tests, p < 0.0001). There was low Sg I expression in RCC. Sg I expression has potential value in predicting cancer progression and prognosis. These findings support the use of Sg I as a novel biomarker for RCC.
drainage. During the operation, the lesion, approximately 3 cm × 1 cm, was found in the ureter about 4 cm away from the bladder, the ureteric segment was excised 1 cm from the tumor and had pathological examination. Results: Postoperative pathological examination with hematoxylin-eosin and immunohistochemical staining (positive expression for synaptophysin, chromogranin A and CD56, Ki 67 70%) indicated LCNEC, and the two cut edges of the ureter were free of tumor. The patient refused either adjuvant chemotherapy or radiotherapy and alive without evidence of tumor recurrence or metastasis for 25 months after surgery. Conclusions: LCNEC is a rare and high aggressive tumor. Pathological examination and immunohistochemical staining are the most important diagnostic procedures. Due to the rarity of ureteral LCNEC, there are no standard treatment options, early surgical treatment may contribute to the prognosis. The First Affiliated Hospital with Nanjing Medical University, Nanjing 210029, ChinaObjective: The incidence of renal cell carcinoma (RCC) has been steadily rising each year. There are currently few recognized biomarkers for the diagnosis and prognosis of RCC. Methods: We investigated semenogelin I (Sg I) expression and its clinical significance in patients with RCC. The expression levels of Sg I and its protein were measured by qPCR and Western blotting, respectively. Immunohistochemistry was used to investigate the protein expression of Sg I in RCC and normal renal tissue from 53 patients. The Kaplan-Meier method and log-rank test were used to evaluate the data. Results: By qRCR (P<0.01) and Western blot, the level of Sg I expression in benign tissues was higher than that in RCC tissues. Expression of Sg I was observed in 30 (57 %) RCC cases, which was significantly lower than that observed in benign renal tissues from the same patients [Sg I positive in 53 (100%) cases (P<0.0001)] by immunohistochemistry. There was an inverse relation between Sg I expression and clinical stage (pT1-2 vs. pT3-4, P<0.0001). Patients with Sg I-negative tumor had a significantly higher risk of recurrence (Kaplan-Meier and log-rank tests, P<0.0001). There was low Sg I expression in RCC. Conclusions: Sg I expression has potential value in predicting cancer progression and prognosis. These findings support the use of Sg I as a novel biomarker for RCC.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.